Stroke Prevention in Nigeria 2 Trial
Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II: A Multicenter, Open-label, Single-arm Type I Hybrid Clinical Trial
Race/ethnicity-specific condition
Phase
PHASE4
Enrollment
220 (est.)
Age range
5 Years to 12 Years
Sex
ALL
Summary
The primary goal of this study is to complete a multicenter single-arm, type I hybrid trial to assess the effectiveness of hydroxyurea therapy for primary stroke prevention in high-risk children with sickle cell anemia (SCA) living in Nigeria in routine care settings.
Conditions studied
Sickle Cell DiseaseStroke
Sign-up window
Aug 5, 2024 – est. completion Dec 31, 2029
Sponsors
Aminu Kano Teaching HospitalCollaborator
Murtala Muhammed Specialist HospitalCollaborator
National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
Vanderbilt University Medical CenterLead
Study locations
Aminu Kano Teaching Hospital
Kano
Shehu U Abdullahi, MD, FWACPaed, CONTACT
Murtala Muhammad Specialist Hospital
Kano
Salma A Suwaid, MBBS FWACP, CONTACT